Eptifibatide Articles
Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016
3 November 2010
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
Sanofi-Aventis’ otamixaban substantially reduced complications of invasive management of acute coronary syndromes
1 September 2009
Integrilin disappoints in EARLY ACS study
9 April 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
Affimed's antithrombotic Ab completes proof-of-concept trial
11 December 2006
Stock Commentary - New York week to Nov 27
4 December 2006
Millennium's 2nd-qtr losses down to $17.7M
7 August 2006
Millennium's 1st-qtr 2006 loss narrows 43%
15 May 2006
Stock Commentary - New York week to Feb 6
13 February 2006
S-P buys exclusive US rights to Integrilin
1 August 2005
Stock Commentary - New York
4 July 2005
Millennium's 1st-qtr losses narrow
9 May 2005
Cardiac benefits reported with Millennium's Integrilin
21 March 2005
Millennium gets $40.0M milestones
14 March 2005
Integrilin shows 24-hr platelet inhibition
7 March 2005
GSK and Millennium sign Integrilin accord
5 July 2004
Stock Commentary - New York
4 August 2003
Generics push S-P profits down 71%
28 July 2003
Second-quarter losses narrow at Millennium
28 July 2003
S-P's new CEO sets out turnaround plan
19 May 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
Millennium losses beat consensus in 4th qtr
3 February 2003
Millennium losses to grow in 2003
20 January 2003
Millennium revenues leap upwards 55%
29 July 2002
Millenium revenues leap 55% in 2nd qtr
29 July 2002
Stock Commentary - New York
22 April 2002
Integrilin pushes up Millennium revenues
22 April 2002
Lovenox plus Integrilin have role in ACS
1 April 2002
NICE "should appraise innovative new drugs a year before launch"
4 February 2002
Millennium Pharma losses widen
28 January 2002
S-P profits hit by charges
28 January 2002
Integrilin cost-effective, says study at AHA
13 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
FDA approves new Integrilin dosing
15 June 2001
Manufacturing woes hit Schering-Plough
18 April 2001
Schering-Plough EPS increases 14.7%
26 January 2001
Disappointing sales for Integrilin; analyst
10 January 2001
Integrilin combination boosts artery patency
15 November 2000
S-P sales growth driven by Claritin
24 October 2000
New study shows no benefit for ReoPro
20 October 2000
NICE-3 shows combination role for LMWH and antiplatelet agents
6 September 2000
Schering-Plough net income up 16%
26 July 2000
World thrombotics market forecasts
3 May 2000
Schering-Plough net income rises 16.5%
26 April 2000
COR Therapeutics boosted by Integrilin
20 April 2000
Genentech unveils new trials for tenecteplase
15 March 2000
COR's Integrilin sales could double to $127M
7 March 2000
Stock Commentary New York
2 March 2000
COR Therapeutics placement worth $250 million
21 February 2000
Stock Commentary New York
10 February 2000
COR boosted on early halt of Integrilin plus stenting study
7 February 2000
Stock Commentary New York
3 February 2000
COR's Integrilin plus thrombolytic in AMI
11 November 1999
Integrilin use in stenting questioned
7 September 1999
Integrilin launched in first Euro markets
8 July 1999
First approval in EU for ReoPro plus stents
9 June 1999
FDA Rejects The Medicine Company's Hirulog
29 October 1998
EPISTENT Update Confirms ReoPro Role In Stenting
1 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
COR Picks Up $24 Mill From Schering-Plough
15 June 1998
Integrilin Launched In First Market, The USA
4 June 1998
Aggrastat, Integrilin First ReoPro Competitors
21 May 1998
Aggrastat Backed For Unstable Angina
14 April 1998
Integrilin "Approvable" In USA For Unstable Angina
8 April 1998
COR Gets Partial OK For Integrilin
4 February 1998
US Biotech Ends Year "Slightly Ahead" Of 1996
21 January 1998
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
Out-Of-Favor Drug Shows Promise In Restenosis
4 September 1997
New York Stock Comment
3 September 1997
COR Therapeutics Boosted By Integrilin Data
28 August 1997
US Quarterly Financial Results Round-Up
12 May 1997
COR Withdraws Integrilin Application
21 April 1997
COR Therapeutics Gets Integrilin Action Letter
26 March 1997
Tirofiban Cuts Mortality In Unstable Angina Patients
26 March 1997
Integrilin Fails To Get US Approval Recommendation
10 March 1997
Schering-Plough Chief Gives R&D Update
10 June 1996
Showing 1-98 of 98 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
